Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Axitinib + Gemcitabine pancreatic cancer not applicable detail...
Unknown unknown Brivanib pancreatic cancer not applicable detail...
Unknown unknown Foretinib pancreatic cancer not applicable detail...
Unknown unknown Nintedanib pancreatic cancer not applicable detail...
Unknown unknown Plicamycin pancreatic cancer not applicable detail...
CDKN2A loss Gemcitabine + Palbociclib pancreatic cancer decreased response detail...
CDKN2A loss GSK461364 + Palbociclib pancreatic cancer decreased response detail...
CDKN2A loss HMN-214 + Palbociclib pancreatic cancer decreased response detail...
SMAD4 del Cisplatin pancreatic cancer sensitive detail...
SMAD4 del Irinotecan pancreatic cancer sensitive detail...
SMAD4 del Gemcitabine pancreatic cancer decreased response detail...
Unknown unknown Gemcitabine + Trametinib pancreatic cancer not applicable detail...
Unknown unknown Golvatinib pancreatic cancer not applicable detail...
Unknown unknown 2G8 pancreatic cancer not applicable detail...
PDGFRA act mut Vistusertib pancreatic cancer predicted - sensitive detail...
Unknown unknown Gemcitabine + PG545 pancreatic cancer not applicable detail...
KDR wild-type Elpamotide + Gemcitabine pancreatic cancer sensitive detail...
Unknown unknown AS-252424 pancreatic cancer not applicable detail...
Unknown unknown Conatumumab + Ganitumab pancreatic cancer not applicable detail...
Unknown unknown Chidamide pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + Pimasertib pancreatic cancer not applicable detail...
Unknown unknown PH11 pancreatic cancer not applicable detail...
Unknown unknown Capecitabine + Cisplatin + Epirubicin + Gemcitabine + Metformin pancreatic cancer no benefit detail...
BRAF V487_P492delinsA LY3009120 pancreatic cancer sensitive detail...
BRAF V487_P492delinsA Trametinib pancreatic cancer sensitive detail...
BRAF V487_P492delinsA Vemurafenib pancreatic cancer resistant detail...
BRAF V487_P492delinsA Dabrafenib pancreatic cancer resistant detail...
SMAD4 dec exp N/A pancreatic cancer not applicable detail...
SMAD4 inact mut Irinotecan pancreatic cancer sensitive detail...
Unknown unknown AIM-100 pancreatic cancer not applicable detail...
Unknown unknown Napabucasin pancreatic cancer not applicable detail...
STK11 D194E STK11 loss Everolimus pancreatic cancer predicted - sensitive detail...
Unknown unknown Metformin pancreatic cancer no benefit detail...
KDR positive TAS-115 pancreatic cancer sensitive detail...
SF3B1 K700E Spliceostatin A pancreatic cancer sensitive detail...
Unknown unknown SRT3025 pancreatic cancer not applicable detail...
Unknown unknown ABTL0812 pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + Nab-paclitaxel + Necuparanib pancreatic cancer not applicable detail...
Unknown unknown Demcizumab + Gemcitabine pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + Vantictumab pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + Uproleselan pancreatic cancer not applicable detail...
Unknown unknown Erlotinib + Gemcitabine pancreatic cancer not applicable detail...
Unknown unknown MitoMet-10 pancreatic cancer not applicable detail...
Unknown unknown CBP501 + Cisplatin pancreatic cancer not applicable detail...
Unknown unknown Bleomycin + CBP501 pancreatic cancer not applicable detail...
Unknown unknown PF-00562271 pancreatic cancer not applicable detail...
ERBB2 positive Trastuzumab deruxtecan pancreatic cancer sensitive detail...
Unknown unknown CG200745 pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + Tacedinaline pancreatic cancer no benefit detail...
ROS1 positive Entrectinib pancreatic cancer predicted - sensitive detail...
Unknown unknown Gemcitabine + Vandetanib pancreatic cancer no benefit detail...
Unknown unknown Gemcitabine + Refametinib pancreatic cancer not applicable detail...
Unknown unknown ABC294640 + Gemcitabine pancreatic cancer not applicable detail...
Unknown unknown MVT-1075 pancreatic cancer not applicable detail...
Unknown unknown MVT-5873 pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + MVT-5873 + Nab-paclitaxel pancreatic cancer not applicable detail...
Unknown unknown Pegilodecakin pancreatic cancer not applicable detail...
Unknown unknown Capecitabine + Pegilodecakin pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + LY2603618 pancreatic cancer no benefit detail...
Unknown unknown Pamiparib + Tislelizumab pancreatic cancer not applicable detail...
Unknown unknown BRD4770 pancreatic cancer not applicable detail...
Unknown unknown G-TPP + Obatoclax pancreatic cancer not applicable detail...
Unknown unknown G-TPP + Navitoclax pancreatic cancer not applicable detail...
BRAF mutant KO-947 pancreatic cancer predicted - sensitive detail...
NRAS mutant KO-947 pancreatic cancer predicted - sensitive detail...
Unknown unknown Berzosertib + Radiotherapy pancreatic cancer not applicable detail...
Unknown unknown Berzosertib + Gemcitabine + Radiotherapy pancreatic cancer not applicable detail...
Unknown unknown Trametinib pancreatic cancer not applicable detail...
Unknown unknown Trabedersen pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + Nimotuzumab pancreatic cancer not applicable detail...
Unknown unknown Galunisertib pancreatic cancer not applicable detail...
Unknown unknown Ensituximab pancreatic cancer not applicable detail...
Unknown unknown CHIR-124 + Gemcitabine pancreatic cancer not applicable detail...
STK11 mutant N/A pancreatic cancer not applicable detail...
CDKN2A mutant N/A pancreatic cancer not applicable detail...
MLH1 mutant N/A pancreatic cancer not applicable detail...
MSH6 mutant N/A pancreatic cancer not applicable detail...
Unknown unknown RX-3117 pancreatic cancer not applicable detail...
Unknown unknown E7449 pancreatic cancer not applicable detail...
ERBB2 amp Pertuzumab + Trastuzumab pancreatic cancer predicted - sensitive detail...
ERBB2 over exp Pertuzumab + Trastuzumab pancreatic cancer predicted - sensitive detail...
Unknown unknown Capecitabine + Gemcitabine + Tertomotide pancreatic cancer no benefit detail...
Unknown unknown SF2523 pancreatic cancer not applicable detail...
BRAF N486_P490del Dabrafenib pancreatic cancer predicted - sensitive detail...
ETV6 - NTRK3 PLX7486 pancreatic cancer predicted - sensitive detail...
ETV6 - NTRK3 MAP2K1 P124S LOXO-195 pancreatic cancer predicted - resistant detail...
Unknown unknown LOAd703 pancreatic cancer not applicable detail...
Unknown unknown Gemcitabine + LOAd703 pancreatic cancer not applicable detail...
CDKN2A loss Palbociclib pancreatic cancer no benefit detail...
CDKN2A mutant Palbociclib pancreatic cancer no benefit detail...
Unknown unknown PF-06840003 pancreatic cancer not applicable detail...
Unknown unknown OBI-999 pancreatic cancer not applicable detail...
Unknown unknown Acalabrutinib + Pembrolizumab pancreatic cancer not applicable detail...
Unknown unknown CAB-AXL-ADC pancreatic cancer not applicable detail...
SF3B1 K700E H3B-8800 pancreatic cancer sensitive detail...
RET fusion BLU-667 pancreatic cancer predicted - sensitive detail...
Unknown unknown GP-2250 pancreatic cancer not applicable detail...
Unknown unknown siG12D-LODER pancreatic cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00871169 Phase II Cetuximab + Irinotecan + Oxaliplatin Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer Completed
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01384253 Phase I 212Pb-TCMC-Trastuzumab + Trastuzumab Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Completed
NCT01497392 Phase I Gemcitabine Dovitinib Capecitabine Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers Completed
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Active, not recruiting
NCT01676259 Phase II Gemcitabine + Nab-paclitaxel + siG12D-LODER Gemcitabine + Nab-paclitaxel A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer (PROTACT) Recruiting
NCT01822756 Phase I Ruxolitinib An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors Terminated
NCT01888965 Phase II Dovitinib Maintenance Dovitinib for Colorectal and Pancreas Cancer Terminated
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01989546 Phase Ib/II Talazoparib Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Completed
NCT02030067 Phase Ib/II RX-3117 Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies Completed
NCT02048943 Phase I Dovitinib + Gemcitabine + Nab-paclitaxel Nab-paclitaxel Dovitinib Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer Withdrawn
NCT02154737 Phase I Erlotinib + Gemcitabine Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer Active, not recruiting
NCT02237157 Phase I Gemcitabine A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Completed
NCT02305186 Phase Ib/II Pembrolizumab Capecitabine Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer Active, not recruiting
NCT02341625 Phase Ib/II BMS-986148 BMS-986148 + Nivolumab A Study of BMS-986148 in Patients With Select Advanced Solid Tumors Active, not recruiting
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Recruiting
NCT02451553 Phase I Afatinib Capecitabine Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Recruiting
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed
NCT02546531 Phase I Defactinib + Gemcitabine + Pembrolizumab Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer Active, not recruiting
NCT02559674 Phase Ib/II ALT-803 + Gemcitabine + Nab-paclitaxel ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel Completed
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Terminated
NCT02581215 Phase II Ramucirumab Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer Active, not recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Terminated
NCT02661542 Phase Ib/II FF-10502 Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas Active, not recruiting
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated
NCT02713529 Phase Ib/II AMG 820 + Pembrolizumab Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer Completed
NCT02715531 Phase I Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors Active, not recruiting
NCT02744287 Phase Ib/II BPX-601 + Rimiducid Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors Recruiting
NCT02760797 Phase I Emactuzumab + Selicrelumab A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT02829099 Phase I JNJ-64457107 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Active, not recruiting
NCT02829723 Phase Ib/II BLZ945 BLZ945 + Spartalizumab Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors Recruiting
NCT02897375 Phase I Cisplatin + Palbociclib Carboplatin + Palbociclib Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Recruiting
NCT02912949 Phase Ib/II Zenocutuzumab A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion Recruiting
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Active, not recruiting
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Completed
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting
NCT02983578 Phase II AZD9150 + Durvalumab AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer Active, not recruiting
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Recruiting
NCT03023722 Phase II Anetumab ravtansine Phase II Anetumab Ravtansine as 2nd Line Treatment for Pancreatic Cancer Completed
NCT03033225 Phase II Verteporfin EUS-guided PDT in Pancreatic Tumors Recruiting
NCT03040986 Phase II Selumetinib Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations Active, not recruiting
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting
NCT03080974 Phase II Nivolumab Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma Recruiting
NCT03087591 Phase I APN401 APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Active, not recruiting
NCT03098160 Phase I Evofosfamide + Ipilimumab Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Unknown status
NCT03136406 Phase Ib/II GI-4000 Leucovorin Avelumab Nab-paclitaxel Bevacizumab Cyclophosphamide Capecitabine Oxaliplatin Fluorouracil ETBX-011 ALT-803 QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Active, not recruiting
NCT03161379 Phase II Cyclophosphamide + GVAX pancreatic cancer vaccine + Nivolumab Phase 2 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer Recruiting
NCT03184870 Phase Ib/II BMS-813160 + Fluorouracil + Irinotecan + Leucovorin BMS-813160 + Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel BMS-813160 A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03189914 Phase Ib/II RX-3117 RX-3117 in Combination With Abraxane in Subjects With Metastatic Pancreatic Cancer Completed
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03207867 Phase II PBF-509 + Spartalizumab A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03257761 Phase I Durvalumab + Guadecitabine Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting
NCT03329248 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin ALT-803 + Avelumab + Bevacizumab + ETBX-011 + GI-4000 Capecitabine + Cyclophosphamide + Nab-paclitaxel QUILT-3.060: Combination Immunotherapy With High-affinity Natural Killer (haNK) in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy. Active, not recruiting
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Active, not recruiting
NCT03454035 Phase I Palbociclib + Ulixertinib Phase I Trial of Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors Recruiting
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting
NCT03485209 Phase II Tisotumab Vedotin Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting
NCT03556228 Phase I VMD-928 Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma Recruiting
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Active, not recruiting
NCT03599362 Phase II Cabiralizumab + Nivolumab Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer Completed
NCT03601923 Phase II Niraparib Niraparib in Patients With Pancreatic Cancer Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated
NCT03784677 Phase I SOR-C13 SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Recruiting
NCT03785210 Phase II Nivolumab + Tadalafil + Vancomycin Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Recruiting
NCT03919292 Phase Ib/II Divalproex sodium + Neratinib Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca Recruiting
NCT03943004 Phase I DFP-14927 Trial of DFP-14927 in Advanced Solid Tumors Recruiting
NCT03997968 Phase Ib/II CYT01B A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors Recruiting
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Recruiting
NCT04117087 Phase I Ipilimumab + Nivolumab + Poly ICLC Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer Recruiting
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Recruiting
NCT04148937 Phase I LY3475070 LY3475070 + Pembrolizumab A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Recruiting
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting
NCT04182516 Phase I NMS-03305293 Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Recruiting
NCT04203641 Phase Ib/II Doxorubicin + L-DOS47 L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer Recruiting
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Recruiting
NCT04273061 Phase II Atezolizumab Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) Recruiting
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Recruiting
NCT04332653 Phase Ib/II NT-I7 + Pembrolizumab NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Recruiting
NCT04390243 Phase II Binimetinib + Encorafenib Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation Not yet recruiting
NCT04390399 Phase II Fluorouracil + Irinotecan + Leucovorin Aldoxorubicin + ALT-803 + Cyclophosphamide + Gemcitabine + Nab-paclitaxel + PD-L1.t-haNK Aldoxorubicin + Cyclophosphamide + Gemcitabine + Nab-paclitaxel Aldoxorubicin + ALT-803 + Cyclophosphamide + Gemcitabine + Nab-paclitaxel Cyclophosphamide + Gemcitabine + Nab-paclitaxel Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer Recruiting
NCT04396821 Phase I TST001 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Recruiting
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting
NCT04482309 Phase II Trastuzumab deruxtecan A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) Not yet recruiting